DV
Dividend Vision

PSTV — Plus Therapeutics Inc

Plus Therapeutics Inc (PSTV)

Total return is -100.0% over the past 25.1 years, 1025.9 points behind SPY at 925.9%. Its deepest 1-year drawdown was 86.9%.

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing cancer treatments, including radiotherapeutic candidates for central nervous system and solid organ cancers, as well as laboratory-developed tests for tumor cell detection. The company does not currently distribute dividends. This security appeals to investors with high risk tolerance seeking exposure to early-stage cancer treatment development, rather than those seeking current income.

PSTV key facts

Asset type
Stock
Asset class
Equity
Inception date
07/11/2001
Last close
$3.84
Market cap
$26,984,876
Average volume
67471.0
Payment date
08/06/2019
Beta
1.397
Payout ratio
0.0
P/E ratio
0.1788
Forward P/E
0.9696
EPS
$21.93